628 related articles for article (PubMed ID: 11146154)
1. Loss of marrow reserve from dose-intensified chemotherapy results in impaired hematopoietic reconstitution after autologous transplantation: CD34(+), CD34(+)38(-), and week-6 CAFC assays predict poor engraftment.
Robinson SN; Freedman AS; Neuberg DS; Nadler LM; Mauch PM
Exp Hematol; 2000 Dec; 28(12):1325-33. PubMed ID: 11146154
[TBL] [Abstract][Full Text] [Related]
2. CD34(+) cell subsets and long-term culture colony-forming cells evaluated on both autologous and normal bone marrow stroma predict long-term hematopoietic engraftment in patients undergoing autologous peripheral blood stem cell transplantation.
Lanza F; Campioni D; Moretti S; Dominici M; Punturieri M; Focarile E; Pauli S; Dabusti M; Tieghi A; Bacilieri M; Scapoli C; De Angeli C; Galluccio L; Castoldi G
Exp Hematol; 2001 Dec; 29(12):1484-93. PubMed ID: 11750108
[TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation.
Freedman A; Neuberg D; Mauch P; Gribben J; Soiffer R; Anderson K; Robertson M; Fisher DC; Schlossman R; Kroon M; Rhuda C; Kuhlman C; Ritz J; Nadler L
Blood; 1997 Dec; 90(12):4996-5001. PubMed ID: 9389719
[TBL] [Abstract][Full Text] [Related]
4. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
Dreger P; Klöss M; Petersen B; Haferlach T; Löffler H; Loeffler M; Schmitz N
Blood; 1995 Nov; 86(10):3970-8. PubMed ID: 7579368
[TBL] [Abstract][Full Text] [Related]
5. Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF.
Ricca I; Compagno M; Ladetto M; Rocci A; Dell'Aquila M; Omedè P; De Marco F; D'Antico S; Caracciolo D; Ferrero D; Carlo-Stella C; Tarella C
Leukemia; 2005 Apr; 19(4):644-51. PubMed ID: 15716989
[TBL] [Abstract][Full Text] [Related]
6. Role of the CD34+ 38- cells in posttransplant hematopoietic recovery.
Hénon P; Sovalat H; Bourderont D; Ojeda-Uribe M; Arkam Y; Wunder E; Raidot JP; Husseini F; Audhuy B
Stem Cells; 1998; 16 Suppl 1():113-22. PubMed ID: 11012153
[TBL] [Abstract][Full Text] [Related]
7. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
[TBL] [Abstract][Full Text] [Related]
8. Mature human hematopoietic cells in donor bone marrow complicate interpretation of stem/progenitor cell assays in xenogeneic hematopoietic chimeras.
Ramírez M; Rottman GA; Shultz LD; Civin CI
Exp Hematol; 1998 Apr; 26(4):332-44. PubMed ID: 9546317
[TBL] [Abstract][Full Text] [Related]
9. Importance of CD34+ cell subsets in autologous PBSC transplantation: the mulhouse experience using CD34+CD38- cells as predictive tool for hematopoietic engraftment.
Hénon PH; Sovalat H; Bourderont D
J Biol Regul Homeost Agents; 2001; 15(1):62-7. PubMed ID: 11388746
[TBL] [Abstract][Full Text] [Related]
10. Analysis of CD34+ cell subsets in stem cell harvests can more reliably predict rapidity and durability of engraftment than total CD34+ cell dose, but steady state levels do not correlate with bone marrow reserve.
Pratt G; Rawstron AC; English AE; Johnson RJ; Jack AS; Morgan GJ; Smith GM
Br J Haematol; 2001 Sep; 114(4):937-43. PubMed ID: 11564089
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of CD34+ cells, CD34+ subsets, colony forming cells and cobblestone area forming cells in cord blood and bone marrow allografts.
Theilgaard-Mönch K; Raaschou-Jensen K; Heilmann C; Andersen H; Bock J; Russel CA; Vindeløv L; Jacobsen N; Dickmeiss E
Eur J Haematol; 1999 Mar; 62(3):174-83. PubMed ID: 10089895
[TBL] [Abstract][Full Text] [Related]
12. Subsets of CD34+ hematopoietic progenitors and platelet recovery after high dose chemotherapy and peripheral blood stem cell transplantation.
Meldgaard Knudsen L; Jensen L; Jarlbaek L; Hansen PG; Hansen SW; Drivsholm L; Nikolaisen K; Gaarsdal E; Johnsen HE
Haematologica; 1999 Jun; 84(6):517-24. PubMed ID: 10366795
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
14. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma.
Negrin RS; Kusnierz-Glaz CR; Still BJ; Schriber JR; Chao NJ; Long GD; Hoyle C; Hu WW; Horning SJ; Brown BW
Blood; 1995 Jun; 85(11):3334-41. PubMed ID: 7538824
[TBL] [Abstract][Full Text] [Related]
15. Sustained, retransplantable, multilineage engraftment of highly purified adult human bone marrow stem cells in vivo.
Civin CI; Almeida-Porada G; Lee MJ; Olweus J; Terstappen LW; Zanjani ED
Blood; 1996 Dec; 88(11):4102-9. PubMed ID: 8943843
[TBL] [Abstract][Full Text] [Related]
16. Viable CD34+/CD133+ blood progenitor cell dose as a predictor of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
Hicks C; Wong R; Manoharan A; Kwan YL
Ann Hematol; 2007 Aug; 86(8):591-8. PubMed ID: 17492259
[TBL] [Abstract][Full Text] [Related]
17. Primordial role of CD34+ 38- cells in early and late trilineage haemopoietic engraftment after autologous blood cell transplantation.
Hénon P; Sovalat H; Becker M; Arkam Y; Ojeda-Uribe M; Raidot JP; Husseini F; Wunder E; Bourderont D; Audhuy B
Br J Haematol; 1998 Nov; 103(2):568-81. PubMed ID: 9827938
[TBL] [Abstract][Full Text] [Related]
18. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma.
Bastion Y; Brice P; Haioun C; Sonet A; Salles G; Marolleau JP; Espinouse D; Reyes F; Gisselbrecht C; Coiffier B
Blood; 1995 Oct; 86(8):3257-62. PubMed ID: 7579423
[TBL] [Abstract][Full Text] [Related]
19. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
20. Assessment of bone marrow stem cell reserve and function and stromal cell function in patients with autoimmune cytopenias.
Papadaki HA; Gibson FM; Rizzo S; Gordon-Smith EC; Marsh JC
Blood; 2000 Nov; 96(9):3272-5. PubMed ID: 11050013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
